Engineered MSCs for Type 1 Diabetes Graft Survival
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Type 1 diabetes mellitus treatment faces challenges due to poor graft survival of β-cells from alloimmune and autoimmune rejection, and the complexity of co-transplanting multiple cell types, leading to short-lived MSC survival and increased immune response risks.
Innovation Solution
Engineered cells are developed to express immunomodulatory, anti-fibrotic, and regenerative proteins, such as IL-10 and Reg proteins, through CRISPR-mediated gene editing, which are designed to minimize immune response and enhance survival by inserting polynucleotides encoding these proteins into endogenous genes, allowing for sustained therapeutic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If β-cell transplantation is performed to treat Type 1 diabetes, then insulin independence can be restored, but graft survival is poor due to alloimmune and autoimmune rejection
Solution Approach 1:
The patent introduces mesenchymal stem cells (MSCs) as intermediary cells that co-transplant with β-cells to mediate immunomodulation. The MSCs interact with dendritic cells and T cells to suppress immune rejection, protecting the β-cell graft from alloimmune and autoimmune attacks while maintaining therapeutic function
Solution Approach 2:
The patent genetically modifies MSCs to overexpress immunomodulatory cytokines (IL-10, IL-4, IL-2) and anti-fibrotic factors (TGF-β). This parameter change in cytokine expression levels enhances the immunoprotective effect, transforming standard MSCs into engineered cells with superior graft survival capabilities
2Reliability
If global immunosuppressants are administered to decrease islet rejection, then graft survival improves, but risk for opportunistic infections increases
Solution Approach 1:
The patent employs local immunomodulation at the graft site through engineered MSCs that secrete immunosuppressive cytokines specifically where needed. This localized approach protects the graft from rejection without causing systemic immunosuppression, thereby avoiding the risk of opportunistic infections associated with global immunosuppressant therapy
Solution Approach 2:
The engineered MSCs provide self-service immunoprotection by autonomously secreting immunomodulatory factors (IL-10, IL-4, IL-2) and anti-fibrotic proteins at the transplantation site. This self-regulating mechanism eliminates the need for external immunosuppressant medications and their associated infection risks
3Duration of action of stationary object
If multiple cell types are co-transplanted to prolong graft functionality, then therapeutic effect is enhanced, but treatment complexity increases
Solution Approach 1:
The patent engineers MSCs to perform multiple functions simultaneously: immunomodulation through cytokine secretion (IL-10, IL-4, IL-2), anti-fibrotic protection via TGF-β expression, and promotion of β-cell survival and regeneration. This multi-functionality consolidates the benefits of multiple cell types into a single engineered cell population, reducing transplantation complexity while maintaining enhanced graft functionality
Data Source
AI summary
An engineered cell is provided that may include one or more polynucleotides inserted into a sequence of a secretory protein of the cell, which may be a β-cell.